NovaBridge Biosciences
NBP evidence brief
What we can confirm
- Market Cap:
- $186.2M
What it means
What to watch
Prepared research question
What matters most for NBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NBP
NovaBridge Biosciences (NBP) is a clinical-stage biotechnology company headquartered in Rockville, MD, focused on developing a pipeline of bispecific antibody drug candidates, including givastomig, uliledlimab, ragistomig, and VIS-101, with no approved products or commercial revenue to date [sec · filed 2026-04-07].
Key risk: No revenue or approved products
Market Cap
$186.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
NovaBridge Biosciences (NBP) is a clinical-stage biotechnology company headquartered in Rockville, MD, focused on developing a pipeline of bispecific antibody drug candidates, including givastomig, uliledlimab, ragistomig, and VIS-101, with no approved products or commercial revenue to date [sec · filed 2026-04-07].
- NovaBridge's pipeline includes four clinical-stage drug candidates: givastomig, uliledlimab, ragistomig, and VIS-101 [sec · filed 2026-04-07].
- The company has not generated any revenue from product sales for the nine months ended September 30, 2025 and 2024 [sec · filed 2025-12-18].
- In 2025, NovaBridge published first-in-human monotherapy data for givastomig in Clinical Cancer Research and presented Phase 1b dose escalation data at the Society for Medical Oncology Gastrointestinal Cancers Congress [sec · filed 2026-04-07].
- NovaBridge completed an underwritten offering on August 1, 2025, issuing 33,333,330 ADSs at $1.95 per ADS [sec · filed 2025-10-06].
- The company announced a new business model to transition into a biotechnology platform company and submitted a listing application on the Hong Kong Stock Exchange on October 31, 2025 [sec · filed 2026-04-07].
What works
- NovaBridge has advanced its lead asset givastomig through Phase 1b dose escalation and published peer-reviewed data, indicating progress in clinical development [sec · filed 2026-04-07].
- The company strengthened its intellectual property portfolio for givastomig through the acquisition of Bridge Health [sec · filed 2026-04-07].
- NovaBridge secured a partnership with BMS to use nivolumab in a Phase 1 trial combining givastomig with nivolumab and mFOLFOX6 [sec · filed 2026-04-07].
What to weigh
- NovaBridge has no approved products and has not generated any revenue from product sales as of September 30, 2025 [sec · filed 2025-12-18].
- The company faces significant uncertainty in obtaining additional funding for operations and completing development and commercialization of its drug candidates [sec · filed 2026-04-07].
- NovaBridge's limited financial and managerial resources may cause it to forgo or delay pursuit of other drug candidates or indications [sec · filed 2026-04-07].
- The company's forward-looking statements acknowledge risks including the ability to demonstrate safety and efficacy, and the timing and likelihood of regulatory approvals [sec · filed 2026-01-22].
From the filings
Quoted directly from source documents.
NovaBridge has no approved products and no revenue from product sales.
“Although we currently do not have any product approved for commercial sale and have not generated any revenue from product sales”
SEC filings · December 18, 2025
NovaBridge's pipeline includes givastomig, uliledlimab, ragistomig, and VIS-101.
“givastomig, uliledlimab, ragistomig, and VIS-101”
SEC filings · April 7, 2026
NovaBridge submitted a listing application on the Hong Kong Stock Exchange.
“We subsequently submitted a listing application on October 31, 2025.”
SEC filings · April 7, 2026
Risks & what to watch (3)›
Key risks
- No revenue or approved products — NovaBridge has no approved products and no revenue from product sales as of September 30, 2025 [sec · filed 2025-12-18].
- Funding and development uncertainty — The company's ability to obtain additional funding and complete development of drug candidates is uncertain [sec · filed 2026-04-07].
- Limited resources may miss opportunities — Limited financial and managerial resources may cause NovaBridge to forgo or delay pursuit of other drug candidates or indications [sec · filed 2026-04-07].
What to watch
- Progress of givastomig through ongoing Phase 1b dose expansion and combination trials [sec · filed 2026-04-07].
- Outcome of the Hong Kong Stock Exchange dual primary listing application submitted on October 31, 2025 [sec · filed 2026-04-07].
- Ability to secure additional funding and partnerships to support pipeline development [sec · filed 2026-04-07].
Sources: SEC filings · Generated September 25, 2026 · How we verify sources →
Run NovaBridge Biosciences through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NovaBridge Biosciences facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
48
Total value held
$71.8M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 6,032,650 | $14.8M |
| hhlr advisors, ltd. | 5,980,568 | $14.7M |
| morgan stanley | 3,838,198 | $9.4M |
| siren, l.l.c. | 3,000,000 | $7.4M |
| aihc capital management ltd | 2,262,933 | $5.6M |
| point72 asset management, l.p. | 1,389,403 | $3.4M |
| candriam s.c.a. | 1,132,563 | $2.8M |
| adage capital partners gp, l.l.c. | 1,000,000 | $2.5M |
| woodline partners lp | 700,000 | $1.7M |
| blackrock, inc. | 627,496 | $1.5M |
Showing top 10 of 48 institutional holders of NovaBridge Biosciences. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 8.3%
- Days to cover
- 4.6
- Shares short
- 4,336,667
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NBP short interestFrequently asked questions
What is the AI investment thesis for NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is a clinical-stage biotechnology company headquartered in Rockville, MD, focused on developing a pipeline of bispecific antibody drug candidates, including givastomig, uliledlimab, ragistomig, and VIS-101, with no approved products or commercial revenue to date [sec · filed 2026-04-07].
Who is the CEO of NovaBridge Biosciences?
Dr. Srishti Gupta M.D. is the chief executive officer of NovaBridge Biosciences (NBP).
Where is NovaBridge Biosciences headquartered?
NovaBridge Biosciences (NBP) is headquartered in Rockville, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.